You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

June 11, 2024

Genome Editing in Thai and Indonesian Agricultural Biotechnology

Subscribe to Updates

Advances in biotechnology have enabled the development of a range of new agricultural tools. From DNA sequencing to plant tissue culture and gene editing, these advances are facilitating the development of better crops.

Genetically modified organisms (GMOs) are one well-known example of agricultural biotechnology. GMOs are organisms whose genetic material has been artificially altered by inserting a piece of foreign DNA. This DNA may be synthetic in origin or sourced from other organisms.

Genome editing (also called gene editing or GEd) involves making precise changes to an organism’s genome without the integration of foreign DNA elements. Several approaches to genome editing have been developed. A well-known one is called CRISPR-Cas9, in which scientists make precise “cuts” in the DNA to create a new genetic variation. Unlike with GMOs, this introduces only minor modifications that are indistinguishable from natural mutations, typically by transplanting genes that code desirable traits from one species into another.

GEd technology has been recognized and supported by the Food and Agriculture Organization of the United Nations (FAO). Thirteen FAO-member countries who are also members of the Organization for Economic Cooperation and Development (OECD) announced their support of the use of GEd technology for commercial uses and consumption at a recent WTO meeting. In addition, over 40 countries around the world, such as Argentina, Australia, Brazil, Canada, Chile, China, England, Japan, Kenya, the Philippines, Russia, the UK, and the US, have published policies emphasizing that foods free of transgenes (i.e., foods that do not contain genes transferred from external sources) are not GMOs, concluding that GEd plants are as safe as normal plants.

In February 2024, the European Parliament approved new genomic techniques (NGTs), or GEd. As a result, plants that are produced using GEd technology are not classified by the EU as GMOs, and the EU authorities consider them to be the same as conventional plants.

Thailand’s Stance toward GEd

In Thailand, the Department of Agriculture in the Ministry of Agriculture and Cooperatives (MOAC) views the results of the EU vote as providing timely support for Thailand’s own policy consideration of the issue. The European Parliament has agreed that genome editing technology is highly safe for human health and the environment, and its use can potentially reduce costs and increase the quality and productivity of agriculture. With this development, it is an opportune time for Thailand to accelerate the process of adopting GEd technology in the agricultural sector for food safety and security by drafting guidelines for the application of GEd technology.

Since the beginning of 2024, the MOAC has taken several actions targeting the development of GEd knowledge.

One event the Department of Agriculture organized was a seminar titled “Modern Biotechnology to Solve the Global Crisis and Emerging Pests.” This event was a brainstorming seminar for all stakeholders on how to take advantage of technology that is safe and on par with other countries, as well as creating guidelines for operating and driving GEd technology in Thailand, including communicating with the public and consumers for a better understanding of the safety of GEd technology and its difference from the production of GMOs. The seminar emphasized that Thailand must be able to take advantage of GEd technology in its future planning for addressing global crises and emerging pests that will impact its agricultural sector.

The Department of Agriculture also organized an academic seminar on GEd technology to set a clear national stance on the issue and accelerate communication with the public and consumers that plants produced with GEd technology are different from GMOs. Next, the Department of Agriculture will invite experts from the FAO, from various countries such as Australia, Japan, and the United States, and from the private and public sectors to join together in a push to build confidence in GEd technology and speed up the preparation of operational procedures. Doing so will assist Thailand in leveraging genome editing technology for the agricultural sector for food safety and security through modern biotechnology. The experts mentioned above recognize that NGTs, or GEd, are likely to continue playing an important role in the increasingly dire situations of global warming and global food crises.

Most professionals believe that using GEd technology to modify the genetics of groups of plants that can be naturally hybridized can produce high-yielding plant varieties that are resistant to disease and drought. In addition, they believe that GEd technology will increase nutritional value. Most countries in the world have invested in research into GEd and approved the use of GEd technology, accepting GEd technology for both commercial and consumption purposes, as with conventional crops, to increase national food security.

Early Support for GEd in Thailand

Though the Ministry of Agriculture and Cooperatives in Thailand has not yet issued any draft notifications or announced public hearings regarding the use of GEd, there is progress in the public sector. One project showing that Thailand is ready to support the use of GEd technology was launched when the National Center for Genetic Engineering and Biotechnology (BIOTEC) released a publication looking at the issue of genome editing and providing technical criteria for considering organisms developed with GEd technology.

Under the guidelines, genome-edited plants derived from the use of GEd techniques employing site-directed nucleases (SDNs) are generally classified into three categories:

  • SDN-1 (deletion), site-directed mutagenesis without using a DNA sequence template.;
  • SDN-2 (substitution), site-directed mutagenesis using a DNA sequence template.; and
  • SDN-3 (insertion), site-directed insertion of a gene/large DNA sequence using a DNA sequence template.

The guidelines have not set out criteria for considering organisms developed with genome-editing technology that do not qualify as living beings genetically modified.

In the view of BIOTEC, SDN-1 plants are not considered to be GMOs, while SDN-2 and SDN-3 plants may be considered as such. If a party wishes to use GEd in conjunction with food, a safety assessment by BIOTEC will be required. The required safety assessment for SDN-1 is lower than for SDN-2 and SDN-3.

This is a positive sign showing that Thailand is ready to move forward with GEd technology development. We may see wider discussions, acceptance, and regulations regarding GEd technology in the future.

Indonesia’s Stance toward GEd

In recent discussions on GEd technology, Indonesian authorities agreed that the determination of whether or not genome-edited products are considered genetically modified will be based on the mechanism of genetic repair, in accordance with the definitions set forth in the Cartagena Protocol and Government Regulation No. 21 of 2005 regarding Biosafety of Genetically Modified Products. If the repair mechanism is carried out by involving donors or genes that do not have a taxonomic relationship with the organism that is the subject of the GEd, the genome-edited product is considered genetically modified. However, if it does not involve a donor or genes outside the individual, it can be considered non-genetically modified.

Despite the discussions surrounding genome editing, there are not yet any specific regulations on genome editing in Indonesia. Therefore, based on Government Regulation No. 21 of 2005 regarding Biosafety of Genetically Modified Products, GEd is still considered genetic modification, and genome-edited products must undergo a safety assessment in order to obtain approval from the Biosafety Commission.

The safety assessment procedure for genetically modified food products is overseen by Indonesia’s National Agency of Drug and Food Control, or BPOM, and involves the following steps:

  • Application submission. Applications are submitted through BPOM’s e-filing system. Applicants must also submit supporting documents in accordance with the relevant BPOM regulations regarding genetically modified food products, accompanied by an integrity pact.
  • Data verification process. If the application is not complete, the applicant must supply the required materials within 14 days of receiving notification from the head of BPOM.
  • Biosafety commission assignment. The head of BPOM assigns the Biosafety Commission to conduct a food safety assessment. The Biosafety Commission has the task of providing recommendations to the authorized minister and the head of the authorized non-ministerial government institution (LPNK) in formulating and establishing policies and issuing biosafety certificates for genetically modified products.
  • Assessment by Biosafety Commission. The Biosafety Commission conducts the food safety assessment within 14 days.
  • Assessment by Biosafety Technical Team. The Biosafety Commission may assign the Biosafety Technical Team, which assists the Biosafety Commission in conducting evaluations and technical assessments of biosafety, to conduct a technical document review and perform further testing if necessary. This will be completed within 56 days of receiving the assignment letter from the Biosafety Commission.
  • Technical assessment results. The Biosafety Technical Team submits the results of the technical assessment to the Biosafety Commission within 7 days.
  • Assessment submission to Biosafety Clearing House. The Biosafety Commission submits the technical assessment of the Biosafety Technical Team to the Biosafety Clearing House, a Biosafety Commission tool that serves as a means of communication between the Biosafety Commission and stakeholders, within 15 days.
  • Publication by Biosafety Clearing House. The Biosafety Clearing House publishes a summary of the Biosafety Technical Team’s technical assessment for 60 days to allow the public to comment.
  • Report submission to Biosafety Commission. The Biosafety Clearing House then submits a public response report to the Biosafety Commission.
  • Biosafety Commission recommendation. The Biosafety Commission submits a food safety recommendation to the head of BPOM within 14 days. In submitting recommendations on food safety of Genetically Modified Products to the Head BPOM, taking into account the results of the assessment of the Biosafety Commission Technical Team and input from the public.
  • Issuance of approval by Head of BPOM. The head of BPOM issues a safety certificate and permit for the distribution of the genetically modified food.

Conclusion

As the regulatory landscapes continue to evolve around genome editing technologies in Thailand, Indonesia, and across the globe, businesses operating in the agricultural biotechnology sector must stay vigilant. Navigating the emerging regulations and approval processes will be crucial for companies looking to commercialize new genome-edited crops and food products. Companies must also carefully manage public perception around genome editing, clearly communicating the science and safety assessments behind these innovations. With strategic foresight and regulatory attentiveness, the agricultural biotech industry can capitalize on the promise of genome editing to enhance food security and drive sustainable productivity gains. Businesses primed to leverage genome editing technologies while mitigating regulatory risks will be positioned for leadership in this new age of agricultural biotechnology.

Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Locations

RELATED INSIGHTS​ 

July 11, 2023
Enacted in 2009, Indonesia’s current Law on Health (Law No. 36/2009) is due for a refresh. The government realized that the law has not maintained its relevance when it comes to health trends such as digital health, which refers to the provision of health services online (also commonly known as telemedicine). While regulations and policy blueprints, such as Ministry of Health (MOH) Regulation No. 46/2017 concerning National E-Health Strategies, have addressed these shifting trends, Indonesia’s main health legislation has proved inadequate in this regard. For this reason, the government began making plans for an update to the law, and the first draft Omnibus Health Law was published in March 2023. The law addresses digital health and other important issues in today’s health landscape, and it seeks to promote the use of locally made health supplies. The draft Omnibus Health Law represents a notable step forward, but in its attempt to govern and regulate all aspects of health, there are also some issues in the draft that may overlap with some existing government regulations, such as provisions on Halal certification, compulsory licensing of patents, and addictive substances. This article outlines some of the draft law’s key aspects as well as some potential issues. Digital Health In addressing the growing health trend of telemedicine, the draft law confirms, reinforces, and fills gaps left by Indonesia’s three main regulations concerning telemedicine. namely, MOHR No. 20/2019 concerning Telemedicine, MOHR No. 24/2022 concerning Medical Records, and Medical Council Regulation No. 74/2020 concerning Telemedicine (MCR No. 74/2020). One of these regulations, MOH Regulation No. 20/2019, allows health service facilities to provide telemedicine services to other health service facilities. This covers telemedicine services related to radiology, electrocardiography, ultrasonography, and telemedicine consultancy services—including those that reflect developments in science and technology. This is the only regulation concerning
Read More
July 10, 2023
One of the more positive outcomes of the COVID-19 pandemic is that telemedicine has become remarkably important as an interactive system between patients and healthcare professionals. Thailand, which ranks near the top as a world medical hub, is a highly favored destination in Asia for expat workers. Currently, the Thai market has both Thai-based and foreign-based platforms with information about healthcare providers and telemedicine readily available. “Doctor Locator,” “Weed Map,” and “Find a Teeth Aligner Dentist” are examples of online platforms connecting patients with medical and telemedicine services. These digital platforms provide information about the location of specialized clinics, cannabis dispensaries, pharmacy stores, and orthodontic practitioners in Thailand. These platforms act as intermediaries between medical care businesses and consumers. As actual medical services are not offered or provided, these digital platforms do not have to be regulated under the Medical Facility Act of Thailand. However, healthcare digital platform services that act as an intermediary or conduit managing information used to connect medical clinics or cannabis dispensaries with patients or customers via a computer network are now regulated under the soon-to-be-implemented Royal Decree on Digital Platforms, regardless of whether payment is actually made via the platform. The regulatory authority for this is the Electronic Transactions Development Agency (ETDA). Under this royal decree, digital platform providers that intend to operate a digital platform service must notify the ETDA prior to initiating operations. The extent of the details to be included in the notification to the ETDA will be more comprehensive if the digital platform: has annual revenue (before expenses) for digital platform services within Thailand exceeding THB 1.8 million (approx. USD 51,200) for an individual operator or THB 50 million (approx. USD 1.42 million) for a corporate or entity operator; or has more than 5,000 users (on average) per month. Apart
Read More
July 10, 2023
On June 30, 2023, the Ministry of Health of Vietnam issued Circular No. 14/2023/TT-BYT stipulating the process and procedure for building bidding package prices for procurement of goods and services in the field of medical devices at public health facilities (“Circular 14”). Circular 14 took effect on July 1, 2023, and will be valid through the end of 2023. Circular 14 applies to the procurement of medical devices/equipment and their accessories, spare parts, and supplies, as well as related services of repair, maintenance, inspection, and calibration. Under Circular 14, there are three methods of determining the price of bidding packages: Collecting quotations provided by suppliers of goods and services in the field of medical devices. Surveying the winning bid prices of similar goods and services on the national bidding network system (https://muasamcong.gov.vn). Using the results of price appraisal of a competent state agency that conducts price appraisal, or a specialized price appraisal enterprise. Method (i) must be used first; the two remaining methods can be applied only after method (i) has been unsuccessful. If the investor/procuring entity uses two or more methods to determine the price of bidding packages, it can select the highest price that is suitable to its financial capacity and professional requirements. Circular 14 further sets out the specific step-by-step process to build prices for procuring products and services in the field of medical devices/equipment. Transitional Provision For bidding packages that have already approved a contractor selection plan before July 1, 2023, the approved contractor selection plan will be followed. For bidding packages for which a contractor selection plan has been submitted by the investor/procuring entity but the plan has not yet been approved, the competent person can decide on the approval of the submitted plan or can request the investor/procuring entity to rebuild the bidding
Read More
July 4, 2023
Practitioners from Tilleke & Gibbins’ Vietnam offices contributed content for the latest edition of the Practical Law Life Sciences Global Guide. The guide provides a comparative overview, in Q&A format, of laws and regulations on pharmaceuticals, medical devices, and other life sciences products in dozens of jurisdictions around the world. The Life Sciences Global Guide is divided into two sections: Regulation (see more details here) and Commercialization, which covers the following topics: Overview of the life sciences sector Pricing, government funding, and reimbursement: National health care system, price regulation and reimbursement Distribution and sale Cross-border trade and parallel imports Advertising to the public and engagement with patient organizations Advertising to healthcare professionals and organizations: Gifts and incentives and transparency and disclosure Patents: Conditions for patentability, registration, length of protection, infringement, international treaties Trademarks: Requirements, registration Competition law issues: Authorities and legislation, commercial contracts and competition law, licensing approvals and formalities Product liability: Regulators, medicinal product liability law, liable partners, defenses, product liability claims, remedies Practical Law, produced by Thomson Reuters, is the world’s leading legal know-how resource for business lawyers, publishing a huge range of guides covering hundreds of jurisdictions and practice areas. The full “Life Sciences Commercialization in Vietnam” section can be found on the Practical Law website.
Read More